| [1] |
Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2[J]. Genes Dev, 2008, 22 (7): 894-907.
|
| [2] |
Jurmeister S, Baumann M, Balwierz A, et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F[J]. Mol Cell Biol, 2012, 32(3): 633-51.
|
| [3] |
Cochrane DR, Spoelstra NS, Howe EN, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubuletargeting chemotherapeutic agents[J]. Mol Cancer Ther, 2009, 8( 5): 1055-66.
|
| [4] |
LeskeläS, Leandro-García LJ, Mendiola M, et al. The miR-200 family controls β-tubulin Ⅲ expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients[J]. Endocr Relat Cancer, 2010, 18(1): 85 -95.
|
| [5] |
Bryant JL, Britson J, Balko JM, et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT[J]. Br J Cancer, 2012, 106(1): 148-56.
|
| [6] |
Xu S, Wu JZ, Cao HX, et al. Hypermethylation of miR-200c promoter correlated with EGFR-TKI resistance in lung cancer cells[J] Nanjing Yi Ke Da Xue Xue Bao(Zi Ran Ke Xue Ban), 20 13, 33(1): 1-5. [徐姝, 吴建中, 曹海霞, 等. miR-200c启动子区 甲基化与肺癌细胞对EGFR-TKI耐药相关[J]. 南京医科大学学 报(自然科学版), 2013, 33(1): 1-5.]
|
| [7] |
Chen Y, Zuo J, Zhang XZ, et al. miRNA-200c enhances sensitivity of gastric cancer SGC7901/DDP cells to cisplatin through inhibiting Akt pathway[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2012, 19(6): 582-7. [陈勇, 左静, 张西志, 等. miRNA-200c通过抑制Akt通路提高胃癌SGC7901/DDP细胞对 顺铂的敏感性[J]. 中国肿瘤生物治疗杂志, 2012, 19(6): 582-7.]
|
| [8] |
Chen Y, Sun Y, Chen L, et al. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling[J]. Mol Med Rep, 20 13, 7(5): 1579-84.
|
| [9] |
Zhong M, Ma X, Sun C, et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer[J]. Chem Biol Interact, 2010, 184(3): 43 1-8.
|
| [10] |
Jia G, Zhang WM, Zhou J, et al. Effects of paclitaxel and gefitinib on the proliferation and cell cycle of human lung adenocarcinoma cell SPC-A1[J]. Zhongguo Fei Ai Za Zhi, 2008, 11(3): 339-44. [贾刚, 张为民, 周娟, 等. 紫杉醇与吉非替尼对人肺腺癌细胞 SPC-A1生长及细胞周期的作用[J]. 中国肺癌杂志, 2008, 11(3): 33 9-44.]
|
| [11] |
Van Schaeybroeck S, Kyula J, Kelly DM, et al. Chemotherapyinduced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in nonsmall cell lung cancer cells[J]. Mol Cancer Ther, 2006, 5(5): 11 54-65.
|
| [12] |
Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line—is there a difference?[J]. J Clin Oncol, 2013, 31(8): 1081-8.
|
下载:
